Eyestem files for IND approval for its product to treat geographic atrophy, the largest cause of incurable blindness in the world for people over 50

  • Health
  • June 5, 2023
  • 0 Comments

Bengaluru (Karnataka) [India], June 5: Dry age-related macular degeneration (dry AMD) is the largest cause of incurable blindness in the world for patients over 50 years. 170 million people suffer from this disease around the world, 25 million of which are in India. These numbers will, unfortunately, increase in the coming decades as our population ages. The more severe version of dry AMD is geographic atrophy, and no therapy is available to arrest or reverse this loss of vision.

Eyestem Research today announced the submission of an Investigational New Drug (IND) application to the Central Drugs Standards Control Organization, India (CDSCO) to begin first-in-human trials of Eyecyte-RPEfor subjects with medium- and late-stage geographic atrophy, secondary to dry AMD.

Dr. Rajani Battu, Chief Medical Officer of Eyestem Research, said, “We are excited to start human trials for Eyecyte-RPE. Dry AMD is a huge disease burden, and this therapy has the potential to make a meaningful difference in our patient’s lives.”

Dr. Jogin Desai, Chief Executive Officer of Eyestem Research, said, “Most cell and gene therapy products under development in the West are estimated to cost over US$ 200,000.Our vision is to democratize access to such treatments at a fraction of these costs and begin disruption of the current status quo with our Eyecyte-RPE product.”

Eyestem Research is a deep science company incubated at the Centre for Cellular and Molecular Platforms, Bangalore, and supported by DBT-BIRAC as well as prestigious Indian and global healthcare investors. The IND submission for Eyecyte-RPEis supported by robust GLP toxicology data from Dabur Research Foundation in India and excellent efficacy/safety data in animal models at Oregon Health and Science University. Validation of the injection technique and dose-finding studies were done in advanced animal models at the Singapore Eye Research Institute.

About Eyecyte-RPE

Eyecyte-RPE™ is a patented suspension of iPSC-derived fate-committed retinal pigment epithelium cells, which are highly potent, safe, and efficacious in in-vitro and in-vivo studies. The cells are derived from induced pluripotent stem cells, are allogeneic in nature, and can be stored for long periods of time.

If you have any objection to this press release content, kindly contact pr.error.rectification[at]gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.

The post Eyestem files for IND approval for its product to treat geographic atrophy, the largest cause of incurable blindness in the world for people over 50 first appeared on PNN Digital.

Related Posts

What Will It Take to Keep India Polio-Free? A Question to Reflect on This World Polio Day

Dr Vinay Rai New Delhi [India], November 19: For many parents today, polio is a disease they have only heard about. This reflects one of India’s greatest public-health achievements. Years…

India’s Polio-Free Achievement Must Be Protected by Every Generation

Dr Sudhanshu Grover Chandigarh [India], November 19: India’s polio-free status is a significant public-health milestone, achieved through years of sustained vaccination efforts and robust surveillance. Preserving this achievement requires continued…

You Missed

Fredna Dental Systems Partners with South Korea’s & Introduces BIOTEM AR Implant Technology in India

Fredna Dental Systems Partners with South Korea’s & Introduces BIOTEM AR Implant Technology in India

Make Your Financial Plans Easier with a Personal Loan

Make Your Financial Plans Easier with a Personal Loan

Gohil Group plans G-Farm retail outlets in Ahmedabad and Surat

Gohil Group plans G-Farm retail outlets in Ahmedabad and Surat

P.C. Chandra Group’s 13th Edition of Jahar Lal Chandra Merit Scholarship Programme

P.C. Chandra Group’s 13th Edition of Jahar Lal Chandra Merit Scholarship Programme

Quest Alliance CEO Aakash Sethi Named to TIME100 Next: India, TIME’s Inaugural List of 100 Individuals Defining the Future of India

Quest Alliance CEO Aakash Sethi Named to TIME100 Next: India, TIME’s Inaugural List of 100 Individuals Defining the Future of India

PPFAS Mutual Fund to host 13th unitholders’ meet on 21st November 2026

PPFAS Mutual Fund to host 13th unitholders’ meet on 21st November 2026